A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women

CompletedOBSERVATIONAL
Enrollment

3,087

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2023

Conditions
HIV Infections
Interventions
DRUG

PrEP

Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.

Trial Locations (20)

1864

Perinatal HIV Research Unit (PHRU), Johannesburg

2000

Wits Reproductive Health & HIV Institute (WRHI), Johannesburg

2092

Helen Joseph Hospital--CHRU, Johannesburg

2671

Aurum Institute--Rustenburg, Rustenburg

3370

SA Medical Research Councit, Chatsworth, Chatsworth

Qhakaza Mbokodo Research Clinic, Ladysmith

4001

Maternal Adolescent & Child Health Research (MatCH), Durban

7750

Emavundleni Research Center, DTHF, Nyanga

7784

University of Cape Town--Khayekutsha, Cape Town

University of Zimbabwe, Harare

7975

UCT-Masi, Cape Town

10216

Makerere University, Kampala

312200

Queen Elizabeth Central Hospital, Blantyre

H100

ICAP, eSwatini Prevention Center, Mbabane

00200

Kenya Medical Research Institute (KEMRI), Nairobi

0001

Human Sciences Research Council (HSRC), Pretoria

0152

Setshaba Research Center, Pretoria

0250

Madibeng Centre for Research, Brits

0299

Aurum Institute Klerksdorp (CRS), Klerksdorp

00000

Kamwala Health Centre, Lusaka

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of Washington

OTHER